Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Fibrinolysis, fibrinogen, fibrin
a2AP, PAI, carboxypeptidases
Animal and experimental models
Cell surface receptors
Clinical and epidemiological studies
Fibrinogen and fibrin
New thrombolytic agents and drug design
Non haemostatic functions
Other fibrinolysis, fibrinogen, fibrin
Plasminogen, apo(a) and fragments
Plasminogen activators
Continuing clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in previously treated patients (PTPs)
Shapiro A., Collins P., Tarantino M., Gruppo R., Hay C., Berntorp E., Retzios A., Sensel M., Tonetta S., Ewenstein B.
Contrast media and compounds containing iodine prevent fibrin formation
Stemberger A., Stemberger M., Stemberger M., Brandt S., Thalhammer A.
Effects of different heparins on thrombin-activatable fibrinolysis Inhibitor-TAFI in hemodialyzed patients
Malyszko J., Mysliwiec M.
Effects of strong static magnetic fields on fibrinolysis
Higashi T.
Total fibrin ‘super glue’ components from human plasma: a new blood banking procedure
Shanbrom E., Owens E.
Utilization of monoclonal antibodies for the quantification of molecular markers of hemostasis
Lugovskoy E., Kolesnikova I. M., Gritsenko P. G., Komisarenko S. V.